Terms: = Thyroid cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Treatment
15 results:
1. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary thyroid cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract] [Full Text] [Related]
2. Application of transoral endoscopic parathyroidectomy via vestibular approach, endoscopic parathyroidectomy via areola approach for parathyroid adenoma.
Zhao Q; Wang W; Yu X; Wang Y
Eur Arch Otorhinolaryngol; 2021 May; 278(5):1559-1565. PubMed ID: 32700236
[TBL] [Abstract] [Full Text] [Related]
3. [Effect of Nifuroxazide on Proliferation, Migration, and Invasion of thyroid Papillary Carcinoma Cells].
Hu Y; Liang LB; Zhang Q; Lan F; Lin K; He H; Li SQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Jan; 50(1):48-54. PubMed ID: 31037904
[TBL] [Abstract] [Full Text] [Related]
4. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (timp-1, timp-2) in patients with Graves' orbitopathy.
Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
[TBL] [Abstract] [Full Text] [Related]
5. Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro.
Yu K; Wang T; Li Y; Wang C; Wang X; Zhang M; Xie Y; Li S; An Z; Ye T
Biomed Pharmacother; 2017 Aug; 92():403-411. PubMed ID: 28575805
[TBL] [Abstract] [Full Text] [Related]
6. Warranting investigation of primary lung adenocarcinoma in patients with an extrapulmonary malignancy and lung nodules due to high frequency.
Zhu B; Dalal S; Kamp DW; Lin X
Am J Clin Pathol; 2014 Mar; 141(3):429-36. PubMed ID: 24515772
[TBL] [Abstract] [Full Text] [Related]
7. In papillary thyroid carcinoma, timp-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.
Ilie MI; Lassalle S; Long-Mira E; Hofman V; Zangari J; Bénaim G; Bozec A; Guevara N; Haudebourg J; Birtwisle-Peyrottes I; Santini J; Brest P; Hofman P
Virchows Arch; 2013 Sep; 463(3):437-44. PubMed ID: 23893334
[TBL] [Abstract] [Full Text] [Related]
8. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.
Manson JE; Bassuk SS; Lee IM; Cook NR; Albert MA; Gordon D; Zaharris E; Macfadyen JG; Danielson E; Lin J; Zhang SM; Buring JE
Contemp Clin Trials; 2012 Jan; 33(1):159-71. PubMed ID: 21986389
[TBL] [Abstract] [Full Text] [Related]
9. BRAFV600E mutation, timp-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
[TBL] [Abstract] [Full Text] [Related]
10. Is age an independent risk factor for chemically induced acute myelogenous leukemia in children?
Pyatt DW; Aylward LL; Hays SM
J Toxicol Environ Health B Crit Rev; 2007; 10(5):379-400. PubMed ID: 17687725
[TBL] [Abstract] [Full Text] [Related]
11. [Progress of clinical pathology and application of PET-CT on thyroid carcinoma].
Gao M; Li XL; Yu Y; Sun BC; Li SL; Xu WG
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Jun; 41(6):419-24. PubMed ID: 16927796
[TBL] [Abstract] [Full Text] [Related]
12. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
[TBL] [Abstract] [Full Text] [Related]
13. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function.
Lundholm K; Daneryd P; Bosaeus I; Körner U; Lindholm E
Cancer; 2004 May; 100(9):1967-77. PubMed ID: 15112279
[TBL] [Abstract] [Full Text] [Related]
14. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors timp-2 and timp-3 in normal thyrocytes and thyroid carcinoma cell lines.
Hofmann A; Laue S; Rost AK; Scherbaum WA; Aust G
Thyroid; 1998 Mar; 8(3):203-14. PubMed ID: 9545106
[TBL] [Abstract] [Full Text] [Related]
15. Human thyroid carcinoma cell lines and normal thyrocytes: expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and protein.
Aust G; Hofmann A; Laue S; Rost A; Köhler T; Scherbaum WA
Thyroid; 1997 Oct; 7(5):713-24. PubMed ID: 9349574
[TBL] [Abstract] [Full Text] [Related]
